Novacyt S.A. (NVYTF) Q2 2026 Earnings Call Transcript

Operator

Good morning, and welcome to the Novacyt Group Investor Presentation. [Operator Instructions] I’d now like to welcome our French shareholders. [Foreign Language] I would now like to hand over to Lyn Rees, CEO. Good morning, sir.

Lyn Rees
CEO & Executive Director

Thank you very much, and good morning, everyone, and thank you for joining us this morning for our interim results presentation. Hopefully, by now, Steve and I are faces that are familiar to everyone on this call. And as your CEO and CFO, we’re very much looking forward to sharing another 6 months’ progress that Novacyt has made over another busy, but effective 6-month period.

Just before we dive into the results, a quick recap on who we are as a business. We’re an international molecular diagnostics company with a growing portfolio of clinical assays or tests that are run in the market, instrumentation that is used to run samples and those tests and research tools. Our three core markets are in reproductive health care, precision medicine and infectious disease.

In terms of the operational and post-period highlights, I think I’d like to first focus in on the acquisition of Southern Cross Diagnostics, where we acquired a profitable distributor of diagnostic and life science products in the Australian marketplace.

The Australian diagnostics market is a fast-growing market, and we wanted to get access to that. And since we acquired the business back in March, Southern Cross has delivered just shy of GBP 2 million worth of revenue to our organization, showing it’s a clear contributor to our current growth and hopefully, our future growth. So really, really pleased to share the progress with